Clinical trials: HDV Infection
Hepatitis D, Chronic
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200 mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic…
- Trial name
- LOWR6 (NCT05229991)
- Testing
- Lonafarnib, Ritonavir
- Where
- 3 sites in Israel, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- Soroka University Medical Center
Hepatitis B, Chronic, Hepatitis D
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection.
- Trial name
- NCT04847440
- Testing
- ATI-2173, Viread, AB-729
- Where
- 2 sites in Moldova, Ukraine
- Volunteers
- 40 people
- Sponsor
- Antios Therapeutics, Inc
Delta Hepatitis
Determination of New Detection and Quantification Thresholds for Serological and Molecular Tests for Hepatitis Delta Virus (HDV) Using Capillary Blood on Blotting Paper (DBS)
The Delta hepatitis virus (HDV) is a satellite virus that requires the presence of hepatitis B virus (HBV) for infection. Approximately 5% of HBV-infected individuals, or about 12 million people globally, are also carriers of…
- Trial name
- SACADE (NCT06649396)
- Testing
- Dried Blood Spot, Analysis on plasma
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Hepatitis D, Chronic
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
- Trial name
- NCT05461170
- Testing
- VIR-2218, VIR-3434, NRTI
- Where
- 20 sites in Bulgaria, France and 7 more
- Volunteers
- 95 people
- Sponsor
- Vir Biotechnology, Inc.
Hepatitis D, Hepatitis B
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
In China, there is no recommendation for Hepatitis D virus (HDV) screening, but the fact is estimated that one-third of the world's population of individuals with chronic Hepatitis B virus (HBV) infection live in China while we…
- Conditions
- Hepatitis D, Hepatitis B, Antibodies; Anti-D, RNA Virus Infections
- Trial name
- NCT05394623
- Testing
- HDV-Ab (IgG), HDV-RNA, RNA genotype
- Volunteers
- 5,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
HDV
Thailand HDV Cohort
There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special…
- Trial name
- NCT05350865
- Where
- 4 sites in Thailand
- Volunteers
- 3,296 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Hepatitis D
HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
The aim of this project is to set up a cross-sectional cohort study (France, Germany, The Netherlands, Poland, Spain, Switzerland, Italy, United Kingdom and Portugal) to assess the implementation of EACS guidelines for…
- Trial name
- NCT06264583
- Testing
- HDV screening
- Where
- Germany
- Volunteers
- 8,000 people
- Sponsor
- University Hospital, Bonn
Hepatitis B, Hepatitis D
Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Background: Sudan has a high prevalence of hepatitis B surface antigen (HBsAg), exceeding 8%. The prevalence of hepatitis B varies across different regions of Sudan, ranging from 6.8% in central Sudan to as high as 26% in…
- Conditions
- Hepatitis B, Hepatitis D, Viral Hepatitis
- Trial name
- NCT06360484
- Testing
- investigations for Hepatitis D virus
- Where
- Sudan
- Volunteers
- 90 people
- Sponsor
- National Center for Gastroentestinal and Liver Disease
Chronic Hepatitis Delta
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants.
- Trial name
- NCT07096193
- Testing
- GS-4321
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
HDV Infection
10119473 -VIROMARKERS HDV Biomarkers Study
This is an observational study, in which clinical data, samples, and any other procedures possibly already performed on participants, were performed within the scope of clinical practice or within the scope of otherwise…
- Trial name
- NCT07313358
- Where
- 2 sites in Germany, Italy
- Volunteers
- 220 people
- Sponsor
- University of Rome Tor Vergata
Observe and Describe the Prevalence of Hepatitis D Infection Among HBsAg Positive People
Epidemiological Survey of Hepatitis D Virus Infection in China
This cross-sectional study will screen out hepatitis D virus-infected patients in HBsAg-positive people. Observe and describe the prevalence of hepatitis D infection among HBsAg positive people.
- Trial name
- NCT04483518
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The First Hospital of Jilin University
HDV, HDV Infection
D-SOLVE Cohorts (Cohort A and B)
Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death.
- Conditions
- HDV, HDV Infection, Chronic Liver Disease
- Trial name
- HDV750 (NCT06160635)
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 750 people
- Sponsor
- Hannover Medical School
Hepatitis D
Pegylated Interferon to Treat Chronic Hepatitis D
This study will evaluate the safety and effectiveness of a long-acting form of alpha interferon called pegylated interferon in treating hepatitis D virus (HDV) infection.
- Trial name
- NCT00023322
- Testing
- Peginterferon Alpha-2a
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Compensated Liver Disease (Disorder), Hepatitis D, Chronic
Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection
Finding biomarkers for stopping bulevirtide treatment of patients with hepatitis delta
- Trial name
- BUL-STOP (NCT06603311)
- Testing
- Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection
- Where
- 5 sites in Germany, Italy
- Volunteers
- 20 people
- Sponsor
- Hannover Medical School
Chronic Delta Hepatitis
Titrating-Dose of Lonafarnib in Combination With Ritonavir
A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (HDV)
- Trial name
- LOWR-4 (NCT02527707)
- Testing
- lonafarnib, Ritonavir
- Volunteers
- 15 people
- Sponsor
- EIT Pharma, Inc.
Hepatitis Delta Virus
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral…
- Trial name
- D-LIVR (NCT03719313)
- Testing
- Lonafarnib, Ritonavir, PEG IFN-alfa-2a
- Where
- 116 sites in United States, Belgium and 20 more
- Volunteers
- 407 people
- Sponsor
- Eiger BioPharmaceuticals
Hepatitis D Virus Infection
MIGrant Reflex Test HDV (MIGRED) Project
Our research team has executed a robust strategy to improve viral hepatitis detection and linkage to care in migrants, contributing to the improvement of knowledge on the clinical and virological future of viral hepatitis in this…
- Trial name
- NCT06539052
- Testing
- anti-HDV positive with the reflex testing methodology
- Volunteers
- 7,500 people
- Sponsor
- University of Campania Luigi Vanvitelli
Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD).
- Trial name
- NCT07200908
- Testing
- Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 172 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Liver Disease, Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Background: Infection with hepatitis D virus leads to a chronic liver disease with no effective treatment. Lonafarnib has improved hepatitis D virus levels in blood, but the medication still needs more research.
- Trial name
- NCT03600714
- Testing
- Peg-interferon lambda, Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis D Infection
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta…
- Trial name
- NCT02637999
- Testing
- PEG IFN alfa-2a, Myrcludex B
- Volunteers
- 24 people
- Sponsor
- Hepatera Ltd.